China 2
Now as a sort of counterpoint to "China Biotech Stocks are Diving", there is a secular force at work that looks unstoppable. Still from Tim Opler's report.
Now as a sort of counterpoint to "China Biotech Stocks are Diving", there is a secular force at work that looks unstoppable. Still from Tim Opler's report.
That's the title of an insightful blog post ( from Alex Telford. China's pharmaceutical industry has evolved from primarily manufacturing active pharmaceutical ingredients (APIs) to becoming a significant…
There is a lot of excitement in the biotech and pharma world around Eli Lilly and Company's oral, "small" molecule GLP-1R agonist, Orforglipron, licensed in 2018 from Chinese biotech Chugai Pharmaceutical Co.,…
In the fourth major deal with a Chinese biotech in just a few months ( Merck (MSD) is paying Hengrui Pharma $200m upfront (and up to $1.77bn on milestones plus royalties on net sales if approved) for a…
The eminently quotable Alex Zhavoronkov, the fearless founder and CEO of Insilico Medicine, presented at hashtag#humanx on the same day Insilico announced $110m in funding ( to propel it to a Hong Kong IPO and…
One irregular dispatch when a new piece lands: notes on AI, evolution, complexity, and the biology of discovery. No noise.
Delivered with Buttondown · unsubscribe anytime